Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Market Cap	$2.54B	P/E Ratio	N/A
52W High	$7.18	52W Low	$2.80
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-4.3%	52W Position	8.4%
Overall Score	52	Value Score	60
Quality Score	60	Technical Score	36

EPS Current Est	$-0.93	EPS Next Est	$-0.79
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RXRX	$3.17	+1.93%	5.86M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RXRX	$3.17	+1.9%	5.86M
3
4
5
6

RXRX

RXRX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Recursion Pharmaceuticals Inc. Data in Excel

Get Recursion Pharmaceuticals Inc. Data in Excel